Rapport Therapeutics, Inc. (RAPP) SEC Filings & Earnings Calls

Phase 3 trials not yet initiated; regulatory and commercial risks remain.

“Phase 3 trials expected to begin in second half of 2027; FDA engagement planned.”

Clinical trial failure risk

“We may never obtain regulatory approval for any of our product candidates, and, even if we do, drug commercialization takes several years and millions of dollars in development costs.” · word for word

Need for additional capital

“We will need to raise substantial additional capital in the future.” · word for word

Operating loss history

“We have incurred significant operating losses in each year since our inception.” · word for word

Clinical-stage biotech with no approved products; pipeline failure risk and significant cash burn.

“Net loss of $56.6M, R&D expense $51.4M, no revenue from product sales.”

Clinical trial cost escalation

“Research and development expenses were $32.7 million for the three months ended March 31, 2026, as compared to $19.6 million for the three months ended March 31, 2025. The increase of $13.1 million consisted of the following: • a $7.9 million increase in RAP-219 program costs, which consisted primarily of an increase of $6.8 million in clinical trial costs p” · word for word

Dependence on future capital raises

“We will need to raise substantial additional capital in the future.” · word for word

No approved products or revenue from product sales

“Since our inception in February 2022, we have not generated any revenue from any sources and have incurred significant operating losses and negative cash flows from operations.” · word for word

No approved products; clinical and regulatory risks.

“Clinical-stage biotechnology company with no approved therapies.”

Clinical Development Risk

“advancing our research and development activities, specifically as it relates to our RAP-219 program” · word for word

Financing Risk

“ensuring funding to advance our pipeline” · word for word

Key Person Risk

“CEO base salary $653,120, target bonus 55%... Chief Medical Officer joined in March 2025”

Clinical trial failure risk

“Our business is highly dependent on the success of our product candidates, particularly RAP-219 for focal onset seizures.” · word for word

Funding risk

“We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Regulatory approval uncertainty

“The regulatory approval processes of the Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable.” · word for word

Clinical and regulatory risk; pipeline is early-stage with no approved products.

“clinical-stage biotechnology company; Phase 2a data, Phase 3 not yet initiated”

Clinical-stage biotech with no approved products

“We are a clinical-stage biotechnology company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability.” · word for word

FDA clinical hold on RAP-219 trial

“Our ability to resolve the U.S. Food and Drug Administration’s clinical hold on our Phase 2 proof-of-concept trial of RAP-219 for the treatment of diabetic peripheral neuropathic pain.” · word for word

Dependence on additional funding

“We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.” · word for word

Clinical and regulatory risk; no approved products

“Pre-revenue; depends on successful Phase 3 trials and FDA approval”